Major Depressive Disorder Clinical Trial
Official title:
Exploring Biomarkers for Depression
The purpose of this research is to explore objective biomarkers in voice, physiological, motor, and brain imaging signals that may one day be used to complement clinical evaluation and treatment of depression.
The hypothesis for our work is that dynamical fluctuations of biological signals, such as,
voice, video, pulse rate, oxygen saturation, skin temperature, skin conductivity, motor
response, magnetoencephalography (MEG), and electroencephalography (EEG), are less complex
during depressive than normal phases. There is a great need for objective biomarkers that may
complement current clinical measures to help recognize depression, monitor its severity, and
quantify the effect of interventions and recovery.
Data will be collected from 20 adult participants seeking outpatient treatment for depression
at the Depression and Clinical Research Program at Massachusetts General Hospital (MGH), each
participating for a total of approximately 9 weeks. For correlation of findings, data will
also be collected from 20 subjects who take part in the healthy/control group. The
healthy/control group will participate in a more limited study visit schedule over the course
of 9 weeks, and will not be given any treatment. During study visits, the investigators will
conduct recordings of voice, video, pulse rate, oxygen saturation, body temperature, skin
conductivity, and motor movement at the Department of Psychiatry at MGH. In addition, each
subject may participate in MEG, EEG, and Magnetic Resonance Imaging (MRI) brain imaging
sessions at the Athinoula A. Martinos Center for Biomedical Engineering.
In order to collect relevant data and correlate findings with accepted clinical measures of
depression severity and response to treatment, this study is conducted as a follow-up study
in concert with a typical drug treatment protocol for Major Depressive Disorder (MDD).
Specifically, our measurements will be made in conjunction with a standard of care drug
treatment protocol using the antidepressant medication escitalopram, an FDA-approved
selective serotonin re-uptake inhibitor (SSRI) commonly used to treat depression. The data
will be collected over a period of approximately 9 weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |